C4 Therapeutics, Inc. Financial Ratios
CCCC|FY2025 SEC 10-K data
Includes DuPont ROE decomposition, profitability margins, liquidity ratios, solvency indicators, and earnings quality analysis. All ratios calculated from FY2025 SEC 10-K data.
Key Data Points
- Altman Z-Score -1.14 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
DuPont ROE Decomposition (FY2025)
Return on Equity
-40.9%
Profit Margin
-292.1%
Net Income / Revenue
Asset Turnover
0.10
Revenue / Total Assets
Equity Multiplier
1.40
Total Assets / Equity
Composite: -40.9% (reported: -40.9%)
Profitability
Liquidity
Current Ratio
7.81
Quick Ratio
7.81
Solvency
Interest Coverage
-
Efficiency
Asset Turnover
0.10
Inventory Turnover
-
Days Sales Outstanding
24 days
As of FY2025 · SEC 10-K · Updated Jun 24, 2026
Earnings Quality
Accrual Ratio
-1.8%
+5.6pp YoY
Earnings are roughly in line with operating cash flow.
This metric is for informational purposes only and does not constitute investment advice. Data sourced from SEC EDGAR filings; updates may be delayed.